Back to OREX Stock Lookup
Pages: 1 2 »» Last Page

OREX – Analyst Ratings

Jan 10, 2014 02:34 PM WallachBeth Starts Orexigen (OREX) at Buy; Sees Contrave With Edge Over Peers (ARNA) (VVUS)
Jan 10, 2014 06:52 AM WallachBeth Capital Starts Orexigen Therapeutics (OREX) at Buy
Jan 7, 2014 12:26 PM FDA Approval of Orexigen's (OREX) Contrave Likely on June 10th - Analyst
Dec 12, 2013 08:24 AM Analyst Sees Positive Reimbursement Trends for Obesity Drugs (VVUS) (ARNA) (OREX)
Nov 27, 2013 12:04 PM Recent Contrave Data is Positive for Orexigen's (OREX) Other Weight-Loss Candidate - Analyst
Nov 25, 2013 09:54 AM Summer Street Waves Warning Flag on Orexigen (OREX)
Oct 4, 2013 07:03 AM Orexigen's (OREX) MAA Submission for Contrave Means Trajectory is Panning Out - Analyst
Oct 3, 2013 07:35 AM Cowen Starts Orexigen Therapeutics (OREX) at Outperform
Jun 19, 2013 12:23 PM Bill for Medicare Coverage, AMA Designation Positive for Obesity Drug Makers (ARNA) (VVUS) (OREX) - Leerink Swann
Feb 4, 2013 10:45 AM VIVUS, Inc. (VVUS) Qsymia Prescriptions Show Gains During Slow Holiday Week (ARNA) (OREX)
Jan 17, 2013 07:41 AM Brean Capital Downgrades Vivus (VVUS) to Sell, Low Qsymia Coverage Means Low Sales
Jan 3, 2013 04:50 PM Piper Jaffray Starts Orexigen Therapeutics (OREX) at Overweight
Dec 21, 2012 11:56 AM JPMorgan Confident Orexigen's (OREX) Will Receive FDA Approval; Comments on Meeting
Dec 18, 2012 03:23 PM Orexigen (OREX) Slumps as Many Expected 'Better News' for Contrave
Dec 10, 2012 09:10 AM VIVUS (VVUS) Qsymia Prescriptions Pop Following Thanksgiving Glut (ARNA) (OREX)
Oct 31, 2012 02:18 PM Latest Qsymia Data Shapes Up Potential Bear Case for VIVUS (VVUS) and Peers (ARNA) (OREX)
Oct 23, 2012 07:42 AM Jefferies Boosts Target on Orexigen (OREX) as FDA Gets Close to Admitting Error
Oct 22, 2012 10:08 AM VIVUS (VVUS) Qsymia Prescriptions Keep Chugging, Gain 27%+ Last Week
Oct 8, 2012 12:48 PM VIVUS' (VVUS) Qsymia Prescription Insurer Pay Rate Rose 5% in Week Two
Sep 21, 2012 12:19 PM Not Expecting E.U. Approval for Vivus' (VVUS) Qsiva, Could be a Plus for Orexigen (OREX) - Analyst
Sep 6, 2012 03:42 PM Orexigen (OREX) Surges On 'Aggressive' Buy Calls Ahead of Catalysts
Sep 5, 2012 05:18 PM Credit Suisse Starts Orexigen Therapeutics (OREX) at Outperform
Jul 18, 2012 08:51 AM VIVUS's (VVUS) Qsymia Approval a Clear Positive for Orexigen (OREX) - Leerink
Jul 16, 2012 11:09 AM VIVUS (VVUS) Gets a Boost from Uber-Bullish Orexigen (OREX) Call
Jul 16, 2012 06:55 AM Leerink Swann Resumes Orexigen Therapeutics (OREX) at Outperform
Jul 13, 2012 08:43 AM With Plenty of Good Arguments for Both Bulls and Bears, VIVUS (VVUS) Qnexa Approval at 50/50 - Jefferies
Jun 28, 2012 03:39 PM UPDATE: JPMorgan Upgrades Orexigen Therapeutics (OREX) to Overweight, Best Opportunity in Obesity Space
Jun 28, 2012 10:21 AM Canaccord Genuity Morning Coffee on Arena Pharma. (ARNA): Does This Mean I Can Keep Eating Super-Sized Double Big Mac Meals?
Mar 26, 2012 10:54 AM Leerink Swann Says Orexigen (OREX) is Still the Best Play After Obesity Drug CV Study Briefing Documents, Boosts Target (VVUS)
Mar 12, 2012 09:02 AM Orexigen Therapeutics (OREX) Surges on BofA Upgrade
Mar 12, 2012 06:58 AM BofA/Merrill Lynch Upgrades Orexigen Therapeutics (OREX) to Buy
Feb 23, 2012 11:20 AM Leerink Swann: Buyers of Orexigen Therapeutics (OREX) Into Next Panel; Preferred Small/Midcap Biotech Pick
Dec 16, 2011 10:10 AM Lazard Capital Upgrades Orexigen Therapeutics (OREX) to Neutral
Nov 21, 2011 05:33 PM Collins Stewart Starts BioMimetic Therapeutics (BMTI) at Buy, Price Target Calls for 143% Upside
Sep 23, 2011 12:51 PM Jefferies Raises Price Target on Orexigen Therapeutics (OREX) as Contrave is Back Up & Running
Sep 22, 2011 04:46 PM Needham & Company Maintains a 'Buy' on Vivus (VVUS); Risks Around Topiramate/Phentermine are Manageable
Sep 21, 2011 08:56 AM Brean Murray Carret & Co. Maintains a 'Sell' on Vivus; Orexigen (OREX) News Not Immediately Relevant to VVUS
Sep 21, 2011 07:58 AM JMP Securities Upgrades Orexigen Therapeutics (OREX) to Market Outperform
Sep 21, 2011 07:54 AM Lazard Capital Downgrades Orexigen Therapeutics (OREX) to Sell
Sep 21, 2011 07:27 AM Leerink Swann Upgrades Orexigen Therapeutics (OREX) to Outperform; Contrave Regulatory Path Unexpectedly Clarified
Jun 3, 2011 02:57 PM BofA/Merrill Lynch Cuts Orexigen (OREX) to Neutral Following Sell-Off
Apr 21, 2011 07:38 AM BofA/Merrill Lynch Upgrades Orexigen Therapeutics (OREX) to Buy
Feb 2, 2011 10:41 AM Canaccord Genuity Morning Coffee on Orexigen (OREX): Not Worth The Weight
Feb 2, 2011 08:15 AM Jefferies Downgrades Orexigen Therapeutics (OREX) to Hold, Value Limited Just Beyond Cash After Contrave Failure
Feb 1, 2011 12:51 PM Cowen Sees Orexigen (OREX) Raising $200M in Capital to Finish Contrave Study
Feb 1, 2011 10:06 AM Leerink Swann Downgrades Orexigen Therapeutics (OREX) to Market Perform; Contrave CRL Asks For CV Study Pre-Approval
Feb 1, 2011 09:59 AM Canaccord Genuity Downgrades Orexigen Therapeutics (OREX) to Hold; Worst Case Scenario Occurred
Feb 1, 2011 09:28 AM Orexigen (OREX) Shares Downgraded at JPMorgan, Leerink, Cowen; More Likely to Follow
Jan 31, 2011 02:14 PM Orexigen (OREX) Shares Surge Ahead of FDA Response for Contrave NDA
Jan 31, 2011 09:27 AM Canaccord Genuity maintains a 'Buy' on Orexigen Therapeutics (OREX); PDUFA Expected Today
Pages: 1 2 »» Last Page

Back to OREX Stock Lookup